Skip to content

Multimodal METformin and FINGER lifestyle intervention to prevent cognitive impairment and disability in older adults at risk for dementia: a phase IIb multi-national randomised, controlled trial.

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-500438-27-01
Acronym
21CX6667
Enrollment
300
Registered
2022-07-28
Start date
2023-06-27
Completion date
Unknown
Last updated
2025-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Older adults with risk factors for dementia but dementia free and without substantial cognitive impairment. The intervention is aimed at preventing cognitive decline/dementia.

Brief summary

Composite z- score of an extended Neuropsychological Test Battery (NTB) adapted from the FINGER trial

Detailed description

Composite z-scores for NTB memory, executive function, and processing speed domains (based on FINGER), Clinical Dementia Rating Sum of Boxes, Instrumental Activities of Daily Living, Healthy Lifestyle Index, a composite score based on exercise, diet, lifestyle cardiovascular risk factors, and social and cognitive activity, BMI, waist, waist/hip ratio, blood pressure, lipid profile and glucose metabolism, Incident cardiovascular disease (e.g., myocardial infarction, angina pectoris, transient ischaemic attack, stroke, peripheral artery disease), FINGER healthy diet index, nutrients and food intake, Self-reported and objectively measured levels of physical activity, Short Physical Performance Battery, hand grip strength, and timed 10-meter dual-task test, Center for Epidemiological Studies-Depression Scale, Perceived Stress Scale, Insomnia Severity Index, RAND36 and 15D scales for health-related quality of life, Self-reported and register data for utilisation of healthcare resources

Interventions

DRUGThe placebo will be manufactured based on the Glucophage® XR 500 specifications to be identical to the IMP in all respects
DRUGexcept that for the lack of active substance.
DRUGMETFORMIN HYDROCHLORIDE

Sponsors

Imperial College London
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Composite z- score of an extended Neuropsychological Test Battery (NTB) adapted from the FINGER trial

Secondary

MeasureTime frame
Composite z-scores for NTB memory, executive function, and processing speed domains (based on FINGER), Clinical Dementia Rating Sum of Boxes, Instrumental Activities of Daily Living, Healthy Lifestyle Index, a composite score based on exercise, diet, lifestyle cardiovascular risk factors, and social and cognitive activity, BMI, waist, waist/hip ratio, blood pressure, lipid profile and glucose metabolism, Incident cardiovascular disease (e.g., myocardial infarction, angina pectoris, transient ischaemic attack, stroke, peripheral artery disease), FINGER healthy diet index, nutrients and food intake, Self-reported and objectively measured levels of physical activity, Short Physical Performance Battery, hand grip strength, and timed 10-meter dual-task test, Center for Epidemiological Studies-Depression Scale, Perceived Stress Scale, Insomnia Severity Index, RAND36 and 15D scales for health-related quality of life, Self-reported and register data for utilisation of healthcare resources

Countries

Finland, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026